“The recent surge in MDMA research has demonstrated applications that range far beyond psychiatry, from treating Parkinson’s disease and cancer to promoting trust and emotional bonding.”
Search results
Posted inEditor's Pick
A Rescue Dog Saved Him From Addiction
“I’ll give her the best four months possible.”
Posted inEditor's Pick
Acid Media
“How perforated squares of trippy blotter paper allowed outlaw chemists and wizard-alchemists to dose the world with LSD.”
Posted inEditor's Pick
We Bought Everything Needed to Make $3 Million Worth of Fentanyl. All It Took Was $3,600 and a Web Browser.
“At the tap of a buyer’s smartphone, Chinese chemical sellers will air-ship fentanyl ingredients door-to-door to North America. Reuters purchased enough to make 3 million pills. Such deals are astonishingly easy—and reveal how drug traffickers are eluding efforts to halt the deadly trade behind the fentanyl crisis.”
Posted inEditor's Pick
The Price of Remission
“When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve covered high drug prices as a reporter for years. What I discovered shocked even me.”
Posted inEditor's Pick
Inside Snapchat’s Teen Opioid Crisis
“Law-enforcement sources and grieving families allege that the social media giant Snapchat has helped fuel a teen-overdose epidemic across the country. Now, their parents are fighting back.”
Posted inEditor's Pick
This Is the Hometown of San Francisco’s Drug Dealers
“A housing boom in one area of Honduras, rooted in migration to the U.S., is being fueled by drug sales in San Francisco.”
Posted inEditor's Pick
What If Psychedelics’ Hallucinations Are Just a Side Effect?
“Some neuroscientists now believe that the drugs’ mental-health benefits don’t come from tripping.”
Posted inEditor's Pick
Tripping on LSD at the Dolphin Research Lab
How a 1960s interspecies-communication experiment went haywire.
Posted inEditor's Pick
The Great Psychedelic Experiment
“Researchers mined an old drug forum and fed the entries to an AI. The result could augur a new class of psychedelic-based antidepressants.”
